A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis

Overview of attention for article published in American Journal of Obstetrics & Gynecology, March 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 14 X users
patent: 2 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 79 Mendeley

So far, Altmetric has seen 20 X posts from 14 X users, with an upper bound of 66,318 followers.

RT @IUSTITallinn: A glimmer of hope for women with recurrent vulvovaginal #candidiasis with VT-1161 but new agents very sparse. https://t.c…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 16 additional X posts.